Home  /  Resource Library  /  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies

Key points: Second CD19 CAR T-cell infusions were feasible and induced responses in 39% of patients (complete response, 20%). Durable responses were observed in NHL and CLL patients treated with an increased second CAR T dose. (Abstract only)